Opinion|Videos|February 18, 2025
Treatment Overview in Later-Stage Relapsed/Refractory Multiple Myeloma
Panelists provide a high-level overview of the treatment landscape for later-stage relapsed/refractory multiple myeloma (R/R MM), discussing the latest therapies and emerging treatment options for this patient population.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Moving to other treatment modalities in R/R disease, provide a high-level overview of the treatment landscape in later R/R MM.
Advertisement
Related to this article
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
An OncLive Scientific Interchange and Workshop covered sequencing, toxicity management, and access barriers for CAR T-cell therapy in multiple myeloma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
The FDA accepted a new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed/refractory multiple myeloma.
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
The FDA approved subcutaneous isatuximab delivered via an on-body injector for multiple myeloma.
Advertisement
Advertisement
Trending on OncLive
1
Experts Unpack Crucial Hematologic Oncology Data From ASCO 2026
2
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
3
MYTHOS Misses Prespecified ORR End Point With T-DXd in HER2-Low Salivary Gland Carcinoma
4
Dr Ermann on Real-World Data for Zanubrutinib vs Acalabrutinib in Older CLL
5